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A B S T R A C T
Human immunodeficiency virus (HIV) causes a chronic infection beginning in most
individuals with an acute syndrome followed by an asymptomatic stage and progresses
in untreated adults over a median of 10 years to the late stage called AIDS. The virus
rapidly and enormously replicates from the initiation of infection. The principal immu-
nodeficiency caused by HIV is depletion in the subset of T lymphocytes referred to as
helper T cells. New anti-HIV drugs given in potent combination regimens have demon-
strated impressive efficacy by both clinical and laboratory measures, and have provided
evidence that drugs can suppress HIV replication and disease manifestations. HIV/AIDS
is still uncommon in Croatia. In the period from 1986 to 2000, 171 patients with AIDS
have been reported of whom 101 (59%) died. The incidence of AIDS in 2000 was about 4
cases per million inhabitants. Recent testing of injection drug users at a needle exchange
program (Help, Split) revealed an HIV incidence of about 1%.
Introduction
Untreated human immunodeficiency
virus (HIV) infection progresses relent-
lessly in almost all infected persons from
a clinically silent infection detectable only
by laboratory tests to a state of severely
damaged immunologic function. After a
median time of about 10 years a variety
of clinical syndromes defining the state of
acquired immunodeficiency syndrome
(AIDS) emerge. Although with great indi-
vidual variation, the disease progresses
and, if not treated, eventually causes
death in almost all cases. Often poorly
understood interactions between the host,
HIV, and environmental factors determi-
ne the particular clinical manifestations
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and rate of disease progression for each
individual.
New advances in basic and clinical re-
search in HIV infection have changed the
view of patients, clinicians, and research-
ers. HIV infection is no longer perceived
as a progressive and fatal disease, it is
now sought to be a potentially treatable
chronic illness. New anti-HIV drugs given
in potent combination regimens (HAART
from highly active antiretroviral therapy)
have demonstrated impressive efficacy by
both clinical and laboratory measures,
and have provided evidence that appro-
priate drugs can suppress HIV replica-
tion and disease manifestations.
New techniques for measuring HIV
RNA have been developed. This enabled
more accurate and effective clinical man-
agement, and shortened the time requi-
red to accumulate evidence for drug effi-
cacy in a clinical trial. The discovery of
the high rapid replication rate of HIV in
all stages of disease had important thera-
peutic implications. For example, if repli-
cation is not completely suppressed the
high replication rate will give rise to mu-
tation and selection for drug-resistant HIV
strains. Immune recovery after potent
antiretroviral therapy has also been stud-
ied. There is evidence that adult thymic
function may allow at least partial im-
mune reconstitution in HIV infected pa-
tients even in late stages of the disease.
However, it seems that specific anti-HIV
immune recovery cannot be achieved un-
less perhaps treatment is begun very early
in the course of HIV infection. Unfortu-
nately benefits from recent advances are
not available to many individuals, partic-
ularly to those from developing countries,
but they are very impressive and give
hope that the disease might be better con-
trolled on a worldwide scale. In settings
were HAART is available problems with
adherence, toxicity and resistance have
emerged.
History of the Epidemic and
Identification of the Etiologic Agent
The initial reports in 19811,2 described
Kaposi sarcoma and Pneumocystis carinii
pneumonia in homosexual men, indicat-
ing the presence of a clinical syndrome of
immune deficiency. At that time HIV was
not discovered and not known to cause
this syndrome. The Centers for Disease
Control (CDC) introduced the name »acqui-
red immunodeficiency syndrome« (AIDS)
and formulated a case definition to iden-
tify and report cases, determine the ex-
tent of the epidemic, and obtain clues
about the cause. Case reporting allowed
identification of risk factors associated
with the syndrome. The largest risk gro-
ups in US and Western Europe were ho-
mosexual and bisexual males, the risk be-
ing associated with sex with multiple
partners. The second largest risk groups
were injection drug users. Hemophiliacs,
recipients of blood transfusions and het-
erosexual partners of persons with the
syndrome were also identified as being at
risk. Subsequently, infants born to mot-
her with the syndrome were also identi-
fied as a risk group.
Epidemiological studies showed that
major risk groups differ in various world
populations, reflecting the predominant
transmission mechanisms of the region.
Three patterns of transmission (types I,
II, and III) were proposed. Type I (North
America, Western Europe, and Australia)
was characterized by the disease predo-
minantly in homosexual men, injection
drug users and their sexual partners, and
hemophiliacs and transfusion recipients.
Type II (Africa) had an equally prevalent
disease in males and females, and re-
flects predominantly heterosexual trans-
mission. Type III refers to sparse cases
usually attributable to imported cases
(contaminated blood or contact with an
infected person outside the region).
Epidemiological findings strongly sug-
gested a transmissible viral agent as the
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cause of the epidemic, and in late 1983 a
group of French scientists isolated a newly
recognized retrovirus3. In 1984 two other
independent laboratories reported the
same4,5. Initially different laboratories
assigned different names to the new re-
trovirus, including lymphadenopathy-
-associated virus (LAV), AIDS-associated
retrovirus (ARV), and human T-lympho-
tropic virus III (HTLV-III). »Human im-
munodeficiency virus« became the accep-
ted designation for the retrovirus in 19866.
Later reports described a second, closely
related retrovirus endemic to West Africa
with similar modes of transmission and
associated clinical syndromes7. The ini-
tially discovered retrovirus associated with
most of the world’s HIV disease is now
designated human immunodeficiency vi-
rus type 1 (HIV-1), and the virus detected
primarily in West Africa and rarely in
West Africans residing abroad is now des-
ignated human immunodeficiency virus
type 2 (HIV-2)8. However, »HIV« usually
indicates HIV-1, because HIV-2 is rare in
most parts of the world.
Identification and isolation of HIV en-
abled the development of techniques for
culturing HIV from different specimens.
Subsequently, a relatively convenient and
cost-effective assay that detected antibody
to HIV in the plasma of infected persons
became available in 1984 and 19859,10.
This made possible to screen blood prod-
ucts, detect HIV infection in persons who
did not have CDC-defined AIDS, identify
seroconversions in newly infected persons,
and construct prospective studies to de-
scribe the course of HIV disease in asym-




HIV causes a chronic infection begin-
ning in most individuals with an acute
syndrome followed by an asymptomatic
stage and progresses in untreated adults
over a median of 10 years to the late stage
called »AIDS«. The virus continuously,
rapidly and enormously replicates from
the initiation of infection. This gives rise
to mutations, and as a result the virus di-
versifies. Immune system damage also
begins upon infection. Major immunopa-
thologic processes occur in lymphoid tis-
sue, and the immune system struggles
over years to preserve its function. How-
ever, slowly, but relentlessly essential
components of the host immune system
are destroyed. The host becomes increas-
ingly susceptible to and eventually dies
as a result of complications of opportunis-
tic infections and malignancies resulting
from immune system dysfunction.
The syndrome called AIDS is the late
stage of HIV disease. It was originally de-
fined for surveillance purposes by the CDC
prior to the identification of HIV as the
etiologic agent. The original case defini-
tion was published in September of 198211,
the CDC has subsequently revised this
definition to include additional syndro-
mes recognized as manifestations of ad-
vanced HIV disease (Table 1, 2)12–20. The
definition of AIDS is complex and com-
prehensive, however, for the medical ma-
nagement the presence or absence of AIDS
is irrelevant. Also, due to the recent ad-
vances in antiretroviral therapy, which
may produce improvement in immuno-
logic function and a decline of the inci-
dence of opportunistic infection, the con-
cept of AIDS as end-stage immunodefi-
ciency is somewhat inappropriate. The
1987 CDC definition of AIDS still contin-
ues to be useful as a definition of an end-




The principal immunodeficiency cau-
sed by HIV is a reduction in the subset of
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T lymphocytes referred to as helper or in-
ducer T cells (CD4+ T lymphocytes). CD4+
T lymphocytes are essential for both cel-
lular and humoral immune responses to
microbes and as a result of this depletion,
impaired ability of the immune system to
recognise and respond to antigens occurs.
As the disease progresses, the immune
system looses the ability to recognise an-
tigens and the host becomes susceptible
to opportunistic infections that are other-
wise efficiently controlled by T cell medi-
ated immune response in a healthy indi-
vidual21. Therefore, the progressive deple-
tion of CD4+ T lymphocytes results in the
development of severe immunodeficiency,
increased susceptibility to opportunistic
infections and subsequently death.
However, this model is an oversimplifi-
cation of a complex disturbance of the im-
mune system caused by HIV, which in ad-
dition to depletion also includes abnormal
activation and profound dysfunction of
effector mechanisms of the immune sys-
tem. Abnormalities of immunological
response, for example diminished cellular
response to specific antigens in infected in-
dividuals, are observed before any substan-
tial depletion in the peripheral blood CD4+
T lymphocytes occurs. Therefore, the exact
way in which HIV causes damage the im-
mune system is still controversial.
Transmission, establishment of
infection, initial host immune
system response
The virus may enter the host: 1) thro-
ugh mucous membranes of the vagina,
rectum or urethra (sexual intercourse)
and the upper gastrointestinal tract
(swallowed infected semen, vaginal fluid,
breast milk) or 2) directly into the blood-
stream through infected blood or blood
products (transfusions, use of contami-
nated needles for injecting drugs, sharp
-object injuries, maternal to fetal trans-
mission, traumatic sexual intercourse,
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TABLE 1













1) > 499/mm3 (  29%) A1 B1 C1
2) 200–499/mm3 (14–28%) A2 B2 C2
3) < 200/mm3 (< 14%) A3 B3 C3
* According to CDC19, all patients in categories A3, B3 and C1–3 are reported as AIDS. According
to the European definition20 categories C1–3 are reported as AIDS. AIDS indicator conditions (Ta-
ble 2) include since 1993 three new entries: recurrent bacterial pneumonia, invasive cervical can-
cer and pulmonary tuberculosis.
** Symptomatic condition not included in categories C that are a) attributed to HIV infection or
indicative of a defect in cell-mediated immunity, or b) considered to have a clinical course or man-
agement that is complicated by HIV infection. Examples of B conditions include but are not lim-
ited to bacillary angiomatosis; thrush; vulvovaginal candidiasis that is persistent, frequent, or
poorly responsive to therapy; cervical dysplasia (moderate or severe); cervical carcinoma in situ;
constituional symptoms such as fever (38.5 °C) or diarrhea > 1 month; oral hairy leukoplakia;
Herpes zoster involving two episodes or > 1 dermatome; idiopathic thrombocytopenic purpura;
listeriosis; pelvic inflamatory disease (especially if complicated by a tubo-ovarian abscess); and
peripheral neuropathy.
exposure of broken skin or an open wound).
It seems that the immune response occur-
ring immediately after exposure to HIV
influences the clinical course of the dis-
ease for years to come.
In case of the mucous membrane
transmission of HIV (»local« infection),
the earliest cells that are infected are
mucosal dendritic cells (DC, also known
as Langerhans cells)22. DC are antigen-
-presenting cells (APC) which activate
naive T lymphocytes by efficiently pro-
cessing and presenting immunogenic
peptides in association with the major
histocompatibility complex (MHC) mole-
cules and by expressing costimulatory
molecules and cytokines. Mucosal DC ei-
ther are themselves infected by HIV or
they carry the virus to the regional lymph
nodes. Thus CD4+ lymphocytes in the re-
gional lymph nodes become infected after
contact with DC, and virus replication in-
tensifies prior to the development of an
HIV specific immune response. This in-
tensive replication gives rise to primary
viremia which leads to wide dissemina-
tion of the virus to other lymphoid or-
gans, the brain and other tissues. When
the virus enters the bloodstream directly
(e.g. contaminated needles) it also reaches
lymphoid organs either by the clearing
mechanism of the reticuloendothelial sys-
tem or with or within blood dendritic cells.
DC present HIV antigens to CD4+ and
CD8+ T lymphocytes during antigen pre-
sentation processes in draining lymph
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TABLE 2
INDICATOR CONDITIONS IN CASE DEFINITION OF AIDS
– Candidiasis of esophagus, trachea, bronchi or lungs
– Cervical cancer, invasive*
– Coccidioidomycosis, disseminated or extrapulmonary
– Cryptococcosis, extrapulmonary
– Cryptosporidiosis with diarrhea > 1 month
– Cytomegalovirus disease of any organ other than liver, spleen or lymph nodes
– Herpes simplex with mucoccutaneous ulcer > 1 month or bronchitis, pneuomonitis,
esophagitis
– Histoplasmosis, disseminated or extrapulmonary
– HIV-associated dementia: disabling cognitive and/or other dysfunction interfering with
occupation or activities of daily living
– HIV-associated wasting: involuntary weight loss > 10% of baseline plus chronic diarrhea
(  2 loose stools/day  30 days) or chronic weakness and documented enigmatic fever
 30 days
– Isosporosis with diarrhea > 1 month
– Kaposi’s sarcoma
– Lymphoma, immunoblastic, Burkitt´s or primary CNS
– Mycobacterium avium, disseminated
– Mycobacterium tuberculosis, disseminated or pulmonary*
– Pneumocystis carinii pneumonia
– Pneumonia, recurrent-bacterial (  2 episodes in 12 months*
– Progressive multifocal leukoencephalopathy
– Salmonella septicemia (non-typhoid), recurrent
– Toxoplasmosis of brain
* Added in the revised case definition 1993.
nodes23. The appropriate antigen presen-
tation by DC enables the development of
HIV-specific cytolytic T lymphocyte (CTL)
response that is considered to play a cru-
cial role the control of primary viremia24.
The CTL response protects the host via
two mechanisms: 1) direct recognition
and lysis of HIV-infected cells and 2) the
synthesis of cytokines (primarily chemo-
kines) that inhibit HIV replication.
Primary viremia is accompanied in
the majority of patients with an acute ill-
ness (acute HIV infection) characterized
by fever, lymphadenopathy, pharyngitis,
rash, myalgia or arthralgia, diarrhea and
headache. After primary viremia a level
of steady-state viremia, called viral set
point, is observed. This set point is usu-
ally reached 1 year after infection and
has important prognostic implications.
Seroconversion and asymptomatic
disease
The CTL response is associated with a
sharp reduction in quantitative viral load
in blood, and clinical recovery from acute
HIV infection. It has been shown that
>95% of patients seroconvert, using stan-
dard serologic tests, within 5.8 months
following HIV transmission25,26. During
clinical latency the viral load has reached
a set point. However the level of CD4+ T
lymphocytes in blood decrease gradually.
Major immunopathologic events are no-
ted in lymph nodes. Studies have demon-
strated high concentrations of HIV as
extracellular virus trapped on the folli-
cular dendritic cell processes within ger-
minal centers of lymph nodes. At this
time the lymphoid tissue serves as the
major reservoir for HIV, the follicular
dendritic cells filter and trap virus and
infected CD4+ lymphocytes and the viral
burden in peripheral blood mononuclear
cells is relatively low. With progressive
disease, the lymph node architecture is
disrupted and more and more virions are
released into blood.
Symptomatic disease
In untreated patients after a variable
period, usually measured in years, symp-
toms, including AIDS defining events oc-
cur. When the CD4+ lymphocyte count
falls below 200 cells per microliter the pa-
tients becomes increasingly susceptible
to various opportunistic diseases. As the
disease advances further and the CD4+
count drops below 50 cells/mm3, additional,
often multiple, opportunistic infections are
present. Ultimately death results from
extensive disease of vital organs, bioche-
mical abnormalities, hematopoietic and
circulatory failure.
Determinants of HIV Disease
Progression
The course of HIV infection is quite
variable. A few individuals progress rap-
idly following the acute stage and develop
AIDS and die within months. At the other
extreme, a few untreated individuals, cal-
led »long-term slow progressors« or »long
-term non-progressors« (LTNP)27–32, re-
main well after more than 12 years of in-
fection without apparent clinical or labo-
ratory signs of disease progression. In
recent years significant progress has been
made in identifying some of these factors,
although much remains to be learned and
the clinical utility of present knowledge is
limited. The two most important vari-
ables to predict clinical outcome (time to
AIDS or death) are viral burden as mea-
sured by the level of RNA in plasma and
the CD4+ lymphocyte count33.
Identified factors for HIV disease pro-
gression include HIV characteristics and
replication dynamics (viral virulence, repli-
cation fitness, and genetic diversity), host
genetic determinants (chemokine recep-
tors, HLA), and the immune response (cel-
lular immune response, cytokine milieu).
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HIV determinants
A few number of LTNP have and were
infected initially with a defective virus.
Reports describe HIV-infected individu-
als harboring virus with deletions in the
nef gene, rendering the virus nonviru-
lent34–36. Throughout all stages of HIV in-
fection there is a high rate of HIV replica-
tion. It appears that approximately 1010
virions are produced and cleared from the
circulation each day37,38.
Strains of HIV can also be character-
ized by the ability to fuse CD4+ T lympho-
cytes in vitro, a property called syncy-
tium-induction (SI). HIV strains that are
not syncytium-inducing (NSI) are able to
replicate in macrophages and CD4+ T lym-
phocytes (referred to as M-tropic) and are
predominant strains in acute infection.
SI strains of HIV replicate in CD4+ T lym-
phocytes but poorly in macrophages and
they emerge in advanced HIV disease (T
tropic strains) and are associated with
disease progression. In vitro cultivation
of T-tropic HIV strains in CD4+ T cell
lines creates phenotypic and genotypic al-
terations generating separate, T cell line
adapted (TCLA) strains. In vivo infection
of CD4+ T lymphocytes is established pri-
marily by SI strains and it correlates
with the rapid decline in the population
of these cells39.
Host genetic determinants
Genetically mediated host factors which
are though to influence the rate of HIV
replication and the course of infection in-
clude: 1) antigen processing characteris-
tics, 2) synthesis of  -chemokines, 3) mu-
tations within the genes coding for che-
mokine receptors, 4) endogenous cytokine
synthesis and 5) HLA region polymor-
phism.
Cytokines are a group of biological re-
sponse modifiers that mediate the inter-
cellular interactions and participate in
the effector phases of both natural and
specific immunity. Chemokines are a gro-
up of proinflammatory cytokines that act
as chemoattractants and activators of
leukocytes. Chemokines exert their bio-
logical activity by binding to the chemo-
kine receptors. It is now well established
that HIV uses chemokine receptors, as
coreceptors for entry into a host cells (in
addition to the CD4+ molecule). This has
profoundly changed our knowledge on HIV
infection. M tropic and T tropic HIV stra-
ins use different chemokine receptors as
coreceptors for the entry into a host cell.
The role of chemokines in the biology
of HIV infection was first demonstrated
in 199540. The authors demonstrated the
inhibitory effect of chemokines RANTES,
MIP-1 and MIP-1 on the replication of
M-tropic but not on T-tropic strains of
HIV. Soon after this discovery, the che-
mokine receptor CCR5 (expressed on T
lymphocytes and macrophages) capable
of binding all three chemokines has been
identified and shown to act as a primary
coreceptor for M-tropic strains of HIV41,42.
Subsequent identification of CXCR4 as a
coreceptor for T-tropic strains of HIV-1
completed the picture. So briefly, M-tro-
pic strains use the CCR5 coreceptor, TCLA
strains use CXCR4 and primary T-tropic
strains use both CCR5 and CXCR4. Other
chemokine receptors (CCR2b, CCR3, CCR8
and orphan receptors V28, STRL-33 and
GPR15) can mediate the entry of some
HIV strains in vitro but the significance
of this finding in vivo remains to be deter-
mined. Paxton et al.43 have identified a
group of individuals that have been ex-
posed to HIV but remained uninfected by
M-tropic HIV strains. These individuals
were subsequently shown to be homozy-
gous for a 32 base pair deletion in the
gene coding for a central section of the
CCR5 protein ( 32), the coreceptor used
by M-tropic (R5) strains of HIV. In Cauca-
sians, the frequency of the homozygotes
for  -32 CCR5 is 1%, for heterozygotes
the frequency is between 15–20%. Homo-
zygosity for the  -32 CCR5 allele is asso-
117
J. Begovac et al.: Understanding HIV Infection, Coll. Antropol. 25 (2001) 1: 111–126
ciated with a significant (not absolute)
degree of protection from infection with
R5 strains of HIV-1 in vivo44–48. The im-
pact of the heterozygosity of  -32 CCR5
mutation on the course of HIV infection is
less clear. It has been suggested that he-
terozygosity might be associated with the
slower progression to AIDS and death49,50
however, it is not clear whether or not
this is real or a methodological (e.g. study
design) issue51.
A second genetic variant (CCR2-64I) in
the gene coding for the CCR2 receptor
might also be associated with slower pro-
gression to AIDS in heterozygous or homo-
zygous individuals. It occurs in roughly
2% of African Americans, Caucasians,
Asians, and Hispanics52,53.
A third genetic variant (SDF1–3’A) af-
fects the region of a gene coding for the
chemokine SDF-1, which is the ligand
(the normal binding molecule) for che-
mokine receptor CXCR454. One study has
shown that SDF1–3’A occurred in rou-
ghly 20% of Caucasians, 16% of Hispan-
ics, 6% of African Americans, and 26% of
Asians infected with HIV. Less than 5%
were homozygous. This genetic variant
may offer some protection against infec-
tion, although data supporting this con-
cept is limited. However, homozygosity
for SDF1–3’A seems to be associated with
slower progression, however, this effect
seems to be more marked in later stages
of HIV disease. It is proposed that the
SDF1–3’A variant changes the availabil-
ity of CXCR4 receptors, perhaps by allow-
ing increased synthesis of the SDF-1 pro-
tein and thus blocking or decreasing cell
surface expression of CXCR4. The role of
CXCR4 coreceptor in disease progression
is supported by experiments showing that
influenza virus increase surface expres-
sion of CXCR4 and the rate of infection of
HeLa cells by HIV-1 strains which use
this coreceptor and not CCR555.
HLA genes may determine the kinet-
ics and the affinity of the early oligoclonal
immune response to an initially homoge-
neous HIV isolate and determine the
disease outcome. The Multicenter AIDS
Cohort Studies have shown that the rate
of progression is linked to several MHC
class I or II genes: HLA B35 or HLA
A1-B8-DR3 are associated with progres-
sion and HLA B27-A24-DR1 with slower
progression of HIV infection56. Other stu-
dies support the notion of the genetic de-
terminants of the immune system are im-
portant for the control of HIV infection
but these data should not be overesti-
mated57. Nevertheless a HLA scoring pro-
file has been shown to predict the risk of
HIV disease progression independently of
HIV RNA and CD4+ cell count58.
The two promotor alleles of the IL-10
gene appear to be another host genetic
factor that significantly affects suscepti-
bility to HIV-1 infection and the rate of
disease progression. The IL-10-5’-592A
allele is associated with decreased IL-10
production, individuals carrying it are at
increased risk for HIV-1 infection and ex-
perience more rapid disease progression
compared with individuals homozygous
for the alternative IL-10-5’-592C/C59.
Immune response and cytokines
The immune response that follows pri-
mary infection is of both humoral and cell
mediated type. It is directed against a va-
riety of HIV antigens and viral proteins
produced by infected cells. Since HIV in-
fects CD4+ cells, T lymphocytes with re-
ceptors specific for HIV are most likely to
bind to infected cells and themselves be-
come infected and destroyed. Hence, it is
postulated that relatively early in the
course of infection, specific anti-HIV cel-
lular components of the host defense are
infected and destroyed.
Antibodies are produced to multiple
HIV antigens but their precise functional
significance is unclear. The best studied
were antibodies toward the envelope pro-
teins (gp 120 and gp 41). No convincing
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association between the presence of neu-
tralizing antibodies and the control of vi-
ral replication has been made to date60,61.
Analysis of the antigenic structure of gp
120 showed that most of the envelope
protein surface is hidden from humoral
immune responses62. Most broadly neu-
tralizing antibodies access only two sur-
faces on gp 120 (one that overlaps the
CD4+ binding site and another that over-
laps the chemokine receptor-binding site).
Conformational changes in core gp120
provide additional mechanisms from eva-
sion from the immune response63.
Since it is believed that T cell medi-
ated immunity plays a key role against
most viral infections it is also sought to
be an important component of the host
immune response to HIV. Classic MHC
class I restricted, HIV specific CD8+ CTLs
have been found in the peripheral blood
of patients after a few weeks of HIV infec-
tion. These cells bind and cause lytic de-
struction of target cells. The qualitative
nature of the HIV specific CD8+ lympho-
cyte response is a important predictor of
eventual outcome. Patients who mount a
broad CD8+ CTL response involving sev-
eral clonal types, have a more favorable
clinical course than patients who mount a
more restricted CTL response64–68.
Pathologic consequences of a disrup-
ted and inappropriate cytokine milieu in-
clude inappropriate activation with con-
sequent loss of T cells (e.g., by HIV direct
killing or by apoptosis), impaired cellular
and humoral immune responses, and in-
creased HIV replication. Three types of
specific patterns of cytokine production,
that become disrupted or inappropriate
as HIV disease progresses, have been
identified. Type 1 cytokine pattern (also
known as Th1) favors a strong cellular
immune response (e.g., activation and
proliferation of T cells), consists of higher
levels of IL-2, IL-12, IL-15, IFN-  , and
TNF- . Type 2 cytokine pattern (also
known as Th2) favors a strong humoral
immune response (e.g., activation of B
cells and antibody production) and con-
sists of higher levels of IL-4, IL-5, IL-10,
and IL-13. The third response includes
proinflammatory cytokines such as TNF-
 , IL-1, and IL-6. These cytokines con-
tribute to immune system activation and
in vitro can stimulate HIV replication.
Research suggests that as HIV disease
progresses, the cytokine milieu shifts from
a Type 1 pattern toward a Type 2 and
proinflammatory pattern, changes that
tend to diminish cellular immune respon-
se and increase HIV replication69–73.
HIV and the Pattern of Lymphocyte
Recirculation
It has been postulated that the princi-
pal mechanism responsible for the deple-
tion of CD4+ T lymphocytes in the periph-
eral blood of HIV-infected individuals is
virus-mediated cytolysis and that billions
of CD4+ lymphocytes were produced and
destroyed daily37,38. However, studies
looking at different T cell compartments
have shown depletion of all T cell subsets
not only those with the CD4+ receptor.
Functionally mature T-lymphocytes
emerge from their precursors in the thy-
mus and migrate to the peripheral blood
and lymphoid organs. At this point in
time they are called naive or virgin cells
because they have not yet encountered an
antigen. If a naive T lymphocyte encoun-
ters an antigen for which it is specific in a
lymph node, it will become activated
effector. T lymphocytes recognise pepti-
des derived from antigens that are associ-
ated with MHC molecules on the surface
of APCs. Antigen recognition induces
T lymphocyte activation that subsequen-
tly leads to the secretion of cytokines,
proliferation and the performance of reg-
ulatory or cytolytic function. Most of the
antigen-specific T lymphocytes die by
apoptosis but some of them survive and
develop into antigen-specific memory
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T lymphocytes that initiate larger secon-
dary immune response upon subsequent
exposure to the same antigen.
Over the course of HIV infection there
is a progressive decrease in the number of
both CD4+ and CD8+ naive T lymphocytes
in the peripheral blood74. The discovery
that the depletion of naïve T lymphocytes
during HIV infection is irrespective of the
expression of CD4+ molecule and suscep-
tibility to infection suggested alternative
mechanisms responsible for this deple-
tion. The discovery that HIV profoundly
changes the kinetics of lymphocyte recir-
culation between peripheral blood and
lymphoid organs enabled us to explain
these findings. A comprehensive review
on this subject has been published by
Rosenberg et al.75.
Lymphocytes circulate in the periph-
eral blood for a short time before they ad-
here to high endothelial cells in venules
of lymphoid organs (lymph nodes, tonsils,
Peyers patches) and migrate through their
parenchyma. If lymphocytes do not en-
counter an antigen during their migra-
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TABLE 3
































25.3 million 3.8 million 8.8% 55% Hetero
North Africa
& Middle East
late '80s 400,000 80,000 0.2% 40% Hetero, IDU
South & South-
East Asia
late '80s 5.8 million 780,000 0.56% 35% Hetero, IDU
East Asia
& Pacific












390,000 60,000 2.3% 35% Hetero, MSM
Eastern Europe
& Central Asia















15,000 500 0.13% 10% MSM, IDU
TOTAL 36.1 million 5.3 million 1.1% 47%
* The proportion of adults (15 to 49 years of age) living with HIV/AIDS in 2000, using 2000
population numbers;
** MSM (sexual transmission among men who have sex with men), IDU (transmission through
injecting drug use), Hetero (heterosexual transmission).
tion, they return to the blood via lymph.
Lymphocytes in the peripheral blood rep-
resent only 2% of the complete lympho-
cyte pool within the body and they ex-
change approximately 50 times a day.
The kinetics of exit, migration and re-en-
try of lymphocyte subsets influences the
number of a lymphocyte subset and its
proportion in relation to other subsets.
The most important factors influencing
the pattern and the kinetics of lympho-
cyte recirculation are cytokines IFN- and
TNF-  . In vivo, the injection of these
cytokines causes the depletion of lympho-
cytes from the peripheral blood by reduc-
ing the rate at which they migrate from
the lymph nodes back to the blood.
HIV infection changes the pattern of
lymphocyte recirculation by altering the
composition of CD4+, CD8+ T-lymphocy-
tes and B-lymphocytes within lymphoid
organs and peripheral blood. HIV infec-
tion also induces the synthesis of various
cytokines including IFN- and TNF- and
changes the composition of cells within
lymphoid organs. These changes within
the lymph nodes of HIV-infected persons
include follicular hyperplasia, accumula-
tion of HIV virions attached to the mem-
brane of FDCs and the entrance of HIV-
-infected lymphocytes and macrophages
via afferent lymphaticus. The net result
of this is the reduction in the lymphocyte
migration from the lymphoid tissues back
to the blood. Hence, although there is a
decrease in peripheral blood lymphocyte
subpopulations, the number of CD4+ T
lymphocytes and CD4+/CD8+ ratio in lymph
nodes remains unchanged and decreases
only when blood CD4+/CD8+ ratio drops
to approximately 0.5 (normal value above
1.0). Studies in both human and simian
models of infection have shown a marked
delay in a decline in the CD4+/CD8+ ratio
in lymphoid organs (lymph nodes, tonsils)
compared to peripheral blood.
The concept of HIV-mediated change
in the pattern of lymphocyte migration
provides an explanation how HIV reduces
lymphocytes subpopulations (for example
naïve CD4+ and CD8+ T-lymphocytes) in
the peripheral blood irrespective of the
CD4+ expression on their membrane. It
also explains the initial increase of CD4+
lymphocytes after initiation of HAART.
Successful HAART reduces viral burden,
relieving the immune response causing
many cells trapped in lymph nodes to be-
come redistributed to the blood76,77.
Global HIV/AIDS Statistics
The latest estimates on the HIV/AIDS
pandemic from the Joint United Nations
Programme on HIV/AIDS (UNAIDS) and
the World Health Organization (WHO)
have been released in December 2000
(Table 3)78. It should be stressed that
there are different methods for deriving
estimates of an epidemic79. Although we
are at the end of the second decade of the
HIV epidemic, we cannot see an end to
the spread of HIV infection. The success
seen in some communities and the dra-
matic increase in survival in developed
countries due to combination antiretro-
viral therapy have been overshadowed by
the numbers of new infections in under-
developed countries and by the growing
epidemic in new regions of the world. Un-
fortunately on a global perspective, the
epidemic seems still out of control.
According to the UNAIDS/WHO esti-
mates a total of 36.1 million people are liv-
ing with HIV at the end of 2000. About 10
men, women and children around the
world were infected per minute during
2000, more than 5 million in all. It is esti-
mated that 1.4 million children live with
HIV/AIDS. The total number of AIDS
deaths since the beginning of the epidemic
reached almost 22 million people. There
were 3 million deaths from AIDS in 2000.
More than 95% of all HIV-infected peo-
ple now live in developing countries. 95%
of all deaths occurred also in developing
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countries. These deaths occur primary
among young adults, who would normally
be in their peak productive and reproduc-
tive years. These deaths are reaching
critical levels in some parts of the world,
particularly sub-Saharan Africa, which
has been hardest hit. Child survival is de-
teriorating, life expectancy has declined
10 to 20 years in some countries, the
health care system is now overburdened
with AIDS cases, and 20 to 40 million
children may become orphaned because
of HIV/AIDS.
Sub-Saharan Africa is home of 72% of
individuals who became infected with HIV
in 2000. Since the start of the epidemic,
more than 52 million people living in
Sub-Saharan Africa have been infected
by HIV, of whom 17 million died. Among
newly infected children under age of 15, 9
of 10 infections occurred in this region.
Yet only a tenth of world’s population
lives in Sub-Saharan Africa. However, for
the first time there are signs that HIV in-
cidence may have stabilized in this re-
gion. Although new infections are found
in all African countries, the bulk of new
infections continues to be concentrated in
east and particularly in southern Africa.
In Botswana, Namibia, Swaziland and
Zimbabwe, current estimates show that
between 20–26% of people aged 15–49 are
living with HIV or AIDS. The epidemic
has moved to South Africa as well, which
is now considered the hardest hit country.
HIV infection is also spreading in coun-
tries like Nigeria that had so far a rela-
tively low incidence.
It is now estimated that about 6 mil-
lion of Asians live with HIV/AIDS, the
majority from south and east Asia. The
epidemic is now 7 to 9 years old. The fact
that HIV epidemic is establishing in the
world’s most populated countries such as
India and China is of great concern.
Trends in STDs and HIV in Eastern
Europe are also alarming. A region which
until mid-1990s had only a few cases of
HIV/AIDS in now experiencing rising
trend particularly in drug injection com-
munities. It is now estimated that 700,000
live with HIV in that region. In Russia,
rates of syphilis have increased from aro-
und 10 cases per 100,000 people in the
late 1980s to over 260 cases per 100,000
in late 1990s. The number of new HIV in-
fections in Russia are showing an expo-
nential growth in recent years. Judging
from registered cases a total of about
50,000 new infections occurred in the
year 2000. Many eastern European coun-
tries (Ukraine, Belarus, Moldova, Esto-
nia) experienced a significant rise in new
HIV infections in the late 1990s.
In developed countries (North Amer-
ica, Western Europe), new combinations
of anti-HIV drugs continue to reduce
deaths significantly. However it seems
that there is no significant progress in re-
ducing the number of new infections.
Over the last decade the rate of new in-
fections is stable instead of declining.
During 2000 it is estimated that about
75,000 persons became infected in North
America and Western Europe.
HIV/AIDS in Croatia
HIV/AIDS is still relatively uncommon
in Croatia. The majority (about 68%) of
cases are believed to be imported, hence
Croatia can be defined as a »pattern III
country«. The first cases of AIDS have
been diagnosed in 1986 and until Decem-
ber 2000 a total of 171 cases have been re-
ported (Figure 1). 101 (59%) patients ha-
ve died. There were 14.6% females. The
risk behavior associated with transmis-
sion were: homo/bisexual in 48% cases,
heterosexual 35% cases, and injection
drug use in 8.8%. There were only 8 he-
mophiliacs and only 3 cases of mother to
child transmission. The majority of pa-
tients were between 30 and 39 years old
(37.4%), however, a considerable number
were over 40 years old (46.2%). The cu-
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mulative incidence of AIDS in Croatia is
around 38 cases per million inhabitants,
the incidence for 2000 being 4 per million.
Although the total number of patients is
quite small and no definitive conclusion
can be made, some regional differences in
incidence might exist. The cumulative in-
cidence in the area of Dubrovnik is about
71 per million, Rijeka and Istra 55, Za-
greb 42.5 and Split 38.5 per million. In
the period 1986 to 1998 the most frequent
initial AIDS defining illnesses were Pne-
umocystis carinii penumonia (20%) and
tuberculosis (20%)80. Prior to the intro-
duction of HAART the median survival
after AIDS diagnosis was 15.8 months
and was related to the type of presenting
illness and CD4+ cell count80.
Other available data from HIV testing
(blood donors, data from testing sites)
also suggest that the incidence of HIV in-
fection in Croatia is low. Rates of syphilis
are also constantly low. During 1998 HIV
testing of 82 injection drug users at a nee-
dle exchange program in Split (Help) re-
vealed only one positive result and simi-
lar rates (around 1%) of HIV infection
were observed in 1999 and 2000. It is not
fully understood why the rate of HIV in-
fection in Croatia remains low. HIV infec-
tion was introduced later than in West-
ern countries and educational efforts
started relatively early (in 1987). Testing
of blood donors began in 1987. Injection
drug users were allowed to purchase ster-
ile syringes and needles in pharmacies
since 1987. There is a possibility that the
pattern of behavior of injection drug us-
ers might be different in Croatia than in
other countries (for example the frequency
of needle and syringe sharing, number of
partners, etc). Sexual behavior might also
be different. A survey by Rudan, I. (1996,
unpublished data) has suggested that
adolescents in Croatia have their first
sexual intercourse at a relatively older
age (26% of 17-year-olds had sexual inter-
course). Also about 70% of adolescents
from Zagreb used a condom at the first
sexual intercourse.
Despite the low incidence of HIV infec-
tion in Croatia, there is no room for com-
placency. For example, the number of in-
jection drug users has increased more
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Fig. 1. Number of AIDS cases and number of deaths in Croatia in the period 1986–2000.
Source: Croatian National Institute of Public Health, Zagreb.
than 5 times in recent years in Croatia.
Hence, more needle exchange programs
are needed. We must consistently educate
our people, especially young ones, about
how best to prevent transmission through
safer sex practices. Condoms should be
available. We should continue screening
our blood supply, provide easy access to
treatment of STDs, and give antiretroviral
therapy to infected pregnant women.
In conclusion, since we still lack a vac-
cine we must continue to relay on educa-
tion, behavioral changes, antiretroviral
therapy and other preventive measures
to combat HIV/AIDS. The development of
a protective vaccine remains an uncer-
tainty for the near future, hence we need
to invest more into prevention programs.
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BIOLO[KE, EPIDEMIOLO[KE I KLINI^KE OSNOVE RAZUMIJEVANJA
INFEKCIJE VIRUSOM LJUDSKE IMUNODEFICIJENCIJE
S A @ E T A K
Virus ljudske imunodeficijencije (engl. human immunodeficiency virus, HIV) uzro-
kuje kroni~nu infekciju koja u ve}ine oboljelih po~inje akutnim sindromom iza kojeg
slijedi asimptomatska faza bolesti. U odraslih osoba nelije~ena infekcija uzrokuje pro-
gresiju bolesti tijekom vremenskog razdoblja od 10 godina (medijan) kada se obi~no
razvije kasna faza bolesti koju nazivamo AIDS-om. HIV se izuzetno brzo i u~inkovito
replicira u organizmu od samog po~etka infekcije, uzrokuje depleciju subpopulacije po-
mo}ni~kih T-limfocita i u kona~nici uzrokuje imunodeficijenciju. Kombinacije razli~itih
anti-HIV lijekova nove generacije iznimno su u~inkovite u terapiji HIV infekcije i pre-
ma klini~kim i prema laboratorijskim parametrima. Nova generacija anti-HIV lijekova
omogu}ava sna`nu supresiju replikacije HIV-a odga|aju}i na taj na~in pojavu simp-
toma HIV bolesti. HIV/AIDS je u Hrvatskoj jo{ uvijek rijetka bolest. U razdoblju od
1986. do 2000. registrirana je 171 osoba oboljela od AIDS-a dok je 101 osoba umrla
(59%). U~estalost pojave AIDS-a u 2000. godini iznosila je 4 bolesnika na milijun sta-
novnika. Testiranje intravenskih narkomana provedeno u sklopu programa besplatne
zamjene igala (Help, Split) pokazalo je da u~estalost HIV infekcije u toj grupi iznosi 1%.
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